Feasibility of a Nurse-Supported Mobile App for Self-Help CBT-I in Cancer Caregivers
Launched by THE UNIVERSITY OF HONG KONG · Mar 16, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Informal caregiver (e.g., family members, friends, or neighbors) who co-resides with and provides unpaid care for cancer survivors of any site or stage, with daily contact of at least 4 hours. If two or more caregivers are available for a cancer survivor, the one providing most of the daily care will be included.
- • Able to understand the research procedures, and read and communicate in Chinese
- • Able to use WeChat
- • Insomnia severity index scores \> 7
- Exclusion Criteria:
- • Another sleep disorder (e.g., obstructive sleep apnea, restless leg syndrome, rapid eye movement behavior disorder), besides insomnia, that is not adequately treated
- • Psychotic disorders (e.g., bipolar disorder, schizophrenia); Suicidal ideation with intent and plan OR attempted suicide within the past 2 months
- • Currently taking any psychotropic drugs (e.g., antidepressants, anxiolytics, sleep medications)
- • Unstable or acute medical condition or condition requiring surgery in the next 6 months; Pregnancy; or Epilepsy
- • Currently participating in any other interventional program
- • Prior experience with CBT-I
- • Night, evening, early morning or rotating shift work
- • Currently caring for a cancer patient receiving hospice care
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported